Pharmacology, Toxicology and Pharmaceutical Science
Hepatitis C
100%
Prevalence
92%
Hepatitis C Virus
89%
Elimination
47%
Virus Antibody
44%
HIV
43%
Antimicrobial Resistance
41%
Gram Negative Bacterium
39%
Beetroot
39%
Beet
39%
Pathogen Clearance
39%
Haemophilia A
39%
Acinetobacter Baumannii
39%
Liver Fibrosis
39%
Mixed Infection
39%
Fungal Isolates
39%
Hyaluronic Acid
27%
Candidemia
26%
Candida Albicans
26%
Leukocyte Antigen
26%
Candida
26%
Virus Hepatitis
21%
Klebsiella
19%
Ertapenem
19%
Extended Spectrum Beta Lactamase
19%
Cytokeratin 18
19%
Narcotic Agent
17%
Cytochrome C
15%
Wistar Rat
13%
Experimental Rat
13%
Glutamic Acid
13%
Geotrichum
13%
Mycosis
13%
Aspergillus
13%
Infectious Agent
13%
Meropenem
12%
Chronic Hepatitis C
11%
Liver Cirrhosis
9%
Carbapenem Derivative
9%
Clavulanic Acid
9%
Ampicillin
9%
Amoxicillin
9%
Acinetobacter
9%
Enterobacter
9%
Cotrimoxazole
9%
Penicillin
9%
Enzyme-Linked Immunosorbent Assay
7%
Acute Hepatitis C
5%
Chronic Liver Disease
5%
Comorbidity
5%
Medicine and Dentistry
Prevalence
88%
Hepatitis C
43%
Human Immunodeficiency Virus
43%
Antibiotic Resistance
41%
Liver Fibrosis
39%
Patient with Human Immunodeficiency Virus
39%
Programmed Cell Death
39%
Mixed Infection
39%
Candidemia
39%
Gram-Negative Bacteria
39%
Acinetobacter Baumannii
39%
Assisted Living
39%
Virus Antibody
39%
Hepatitis C Virus
39%
Hepatitis Virus
21%
Keratin 18
21%
Infection Control
20%
Geotrichum
19%
Intensive Care
19%
Lung Lavage
19%
Sputum
19%
Pathogen
19%
Mycosis
19%
Aspergillus
19%
Klebsiella
19%
Extended Spectrum Beta Lactamase
19%
Ertapenem
19%
Cytochrome C
17%
Meropenem
12%
Amoxicillin/Clavulanic Acid
9%
Trimethoprim/Sulfamethoxazole
9%
Carbapenem Derivative
9%
Ampicillin
9%
Escherichia
9%
Acinetobacter
9%
Penicillin
9%
Enzyme Linked Immunosorbent Assay
8%
Hepatocyte
8%
Unprotected Sex
8%
High Risk Population
8%
Antibiogram
7%
Central Venous Catheter
5%
Colistimethate
5%
Amikacin
5%
Imipenem
5%
Hand Hygiene
5%
Acinetobacter Infection
5%
Ciprofloxacin
5%
Bloodstream Infection
5%